AXON Hires Silvia De Carvalho as New Clinical Studies Lead
Former Klick Health Senior Vice President of Activation Strategy, Silvia De Carvalho, moves to front AXON’s clinical studies practice globally as clinical studies lead. She brings almost two decades of healthcare marketing expertise.
De Carvalho started her career working with the clinical development teams at Sanofi to identify optimal protocols and product viability in the diabetes landscape.
“Silvia is a wonderful addition to the AXON team, not only bringing a strong strategic mind to our client business, but also a high level of ambition for what we can achieve,” said Ralph Sutton, international managing partner of AXON, and its parent company AVENIR GLOBAL.
De Carvalho will help shape how AXON will support patients, caregivers, healthcare professionals, and broader stakeholders navigate the healthcare industry.
“Building on a great foundation, I am excited to continue our growth journey alongside our clients. A first key area of focus for us will be an expansion on our digital engagement services and how we can help clients optimally recruit and engage patients and healthcare professionals within digital and decentralized trials, but also effectively embrace adaptive trial design. The second area of focus will be helping clients to reach diverse patient populations to reflect the communities who may benefit from their medicines," said De Carvalho.
Reference
AXON HIRES SILVIA DE CARVALHO AS NEW CLINICAL STUDIES LEAD. (2023, July 17). AXON.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA to Launch National Priority Voucher Program to Speed Drug Reviews for Critical Therapies
June 18th 2025Under the new initiative, companies may receive a voucher enabling FDA review to be shortened from the standard 10–12 months to just 1–2 months following final application submission if the drug addresses US national health priorities.
